8-K Announcements
6Material company update
May 27, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
May 6, 2026·SEC
Aptevo Therapeutics Inc.(APVO)Earnings, Financials & Key Ratios
APVO•NASDAQ
$4.55
Price updated Jun 27, 2026
AboutAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Show more
- Revenue$0
- EBITDA-$26M-7.5%
- Net Income-$26M-7.6%
- EPS (Diluted)-87.27+99.7%
- ROE-234.61%+17.5%
APVO Price & Volume
Aptevo Therapeutics Inc. (APVO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Long-term Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Gap
"Aptevo Therapeutics remains a high-risk, pre-commercial biotechnology entity characterized by a total absence of revenue and a structural reliance on external capital to fund its $3.6 million average quarterly R&D expenditure. The company's financial stability is severely constrained by accumulated losses of $281.9 million, which necessitates frequent, dilutive financing to maintain its clinical-stage pipeline. Investors should monitor the company's ability to secure strategic partnerships, as the current $14.5 million cash position appears insufficient to support long-term operational continuity without further capital raises."
Verdict Logic
the company's precarious liquidity profile, highlighted by a cash position of only $14.5 million against a consistent quarterly burn rate, suggests a high probability of further shareholder dilution.
APVO Growth Metrics
Aptevo Therapeutics Inc. (APVO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-10.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM98.88%
Return on Capital
10 Years-119.41%
5 Years-135.97%
3 Years-162.84%
Last Year-172.38%
APVO Recent Earnings
Aptevo Therapeutics Inc. (APVO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$6.41+0.0%
$6.41
Rev
—
—
Q2 2026
Mar 20, 2026Metric
Actual
Est
EPS
$1684.47+20921.6%
$8.09
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$40.11-6.7%
$37.59
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$151.08-33473.3%
$0.45
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $6.41vs $6.41+0.0% | — |
| Q2 2026 | Mar 20, 2026 | $1684.47vs $8.09+20921.6% | — |
| Q4 2025 | Nov 6, 2025 | $40.11vs $37.59-6.7% | — |
| Q3 2025 | Aug 11, 2025 | $151.08vs $0.45-33473.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Aptevo Therapeutics Inc. (APVO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.55 | $4.83M | -0.05 | — | — | -234.61% | — | |
| $12.11 | $1.12B | -8.53 | 144.57% | -151.12% | — | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $55.83 | $8.55B | 20.16 | 87.32% | 65.95% | 87.36% | — | |
| $2.10 | $244.77M | -1.83 | -51.24% | -2056.79% | -58.89% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — |
Compare APVO vs Peers
Aptevo Therapeutics Inc. (APVO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
APVO SEC Filings & Documents
Aptevo Therapeutics Inc. (APVO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when APVO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
APVO Frequently Asked Questions
Aptevo Therapeutics Inc. (APVO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is APVO profitable?
Aptevo Therapeutics Inc. (APVO) reported a net loss of $26.3M for fiscal year 2025.
Dividend & Returns
What is APVO's return on equity?
Aptevo Therapeutics Inc. (APVO) has a return on equity (ROE) of -234.6%. Negative ROE indicates the company is unprofitable.
What is Aptevo Therapeutics Inc.'s free cash flow?
Aptevo Therapeutics Inc. (APVO) had negative free cash flow of $27.0M in fiscal year 2025, likely due to heavy capital investments.